Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients

BMC Endocrine Disorders

Daniél Vega Møller¹  Morten Hørmann²  Mette Dalsgaard²  Marie Jakobsen² 

[1] Novo Nordisk Scandinavia AB, Arne Jacobsens Allé 17, 9, København, DK-2300, Denmark;COWI A/S, Parallelvej 2, Kongens Lyngby, DK-2800, Denmark

关键词: Health care costs;    Dose;    Type 2 diabetes;    Insulin glargine;    Insulin detemir;   

Others  :  1086166
DOI  :  10.1186/1472-6823-12-21

 received in 2012-06-29, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

The uncertainties regarding dose similarities between basal long-acting insulin analogues remain. Recent real-world studies indicate dose similarities between insulin detemir and insulin glargine, but further studies are still warranted.

The aim of this study was to compare real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients when administered once daily.

Methods

We analysed 536 patient cases from general practice (63%) and endocrinological outpatient clinics (37%). A self-administered questionnaire completed by the treating physician was used to obtain data on patient characteristics (gender, age, weight, height, latest HbA_1c-value), daily doses, administration of and number of years treated with insulin detemir and insulin glargine, concomitant insulin use and use of non-insulin anti-diabetic medication. Both bivariate analyses and multivariate regression analyses were applied to examine whether there were differences in the daily doses of insulin detemir and insulin glargine.

Results

There was no significant difference in the mean daily doses of insulin detemir (0.414 U/kg) and insulin glargine (0.416 U/kg) (p = 0.4341). In multivariate regression analyses, age and BMI had a significant influence on daily insulin dose with the dose increasing 0.003 U/kg (p = 0.0375) and 0.008 U/kg (p = 0.0003) with every 1 increment in age and BMI, respectively.

Conclusions

Dose similarities between insulin detemir and insulin glargine were seen in type 2 diabetes patients when administered once daily. Thus, the use of insulin detemir and insulin glargine is not associated with different medical costs if the price and treating algorithm are similar.

【 授权许可】

   
2012 Jakobsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization. http://www.who.int/mediacentre/factsheets/fs312/en/index.html webcite
• [2]The Danish Diabetes Association. http://www.diabetes.dk/Rundt_om_diabetes/Type_2_diabetes.aspx webcite
• [3]UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853.
• [4]Mudaliar S, Edelman SV: Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001, 30(4):935-982.
• [5]Meneghini L: Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. Int J Clin Pract 2008, 62(8):1255-1264.
• [6]Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ: Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005, 21(2):291-298.
• [7]Heise T, Pieber TR: Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007, 9(5):648-659.
• [8]Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001, 24(2):296-301.
• [9]Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29(6):1269-1274.
• [10]Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006, 28(10):1569-1581.
• [11]Philis-Tsimikas A: An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). Expert Opin Pharmacother 2008, 9(12):2181-2195.
• [12]Hollander P, Cooper J, Bregnhoj J, Pedersen CB: A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008, 30(11):1976-1987.
• [13]Monami M, Marchionni N, Mannucci E: Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008, 81(2):184-189.
• [14]Raskin P, Gylvin T, Weng W, Chaykin L: Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009, 25(6):542-548.
• [15]Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G: A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008, 51(3):408-416.
• [16]Dornhorst A, Luddeke HJ, Koenen C, Merilainen M, King A, Robinson A, et al.: Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab 2008, 10(1):75-81.
• [17]Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ: Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007, 9(3):418-427.
• [18]Fakhoury W, Lockhart I, Kotchie RW, Aagren M, Lereun C: Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology 2008, 82(2):156-163.
• [19]Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B: A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009, 31(3):623-631.
• [20]McAdam-Marx C, Yu J, Bouchard J, Aagren M, Brixner DI: Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin 2010, 26(1):191-201.
• [21]Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM: Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Adv Ther 2010, 27(4):211-222.